Alnylam's vutrisiran gets fast-track treatment at the FDA
FDA has put Alnylam’s RNAi treatment for the polyneuropathy of hereditary transthyretin-mediated amyloidosis on its regulatory fast track. Alnylam secured the designation for the candidate, vutrisiran, ahead of the anticipated readout from a phase 3 trial early next year.
FDA has put Alnylam’s RNAi treatment for the polyneuropathy of hereditary transthyretin-mediated amyloidosis on its regulatory fast track. Alnylam secured the designation for the candidate, vutrisiran, ahead of the anticipated readout from a phase 3 trial early next year.
